Open Access

Low expression of long noncoding RNA CDKN2B-AS1 in patients with idiopathic pulmonary fibrosis predicts lung cancer by regulating the p53-signaling pathway

  • Authors:
    • Yufeng Du
    • Xiaoyan Hao
    • Xuejun Liu
  • View Affiliations

  • Published online on: January 31, 2018     https://doi.org/10.3892/ol.2018.7910
  • Pages: 4912-4918
  • Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The present study aimed to investigate the expression of long non-coding RNA (lncRNA) cyclin dependent kinase inhibitor-2B-antisense RNA 1 CDKN2B‑AS1 in patients with peripheral blood of idiopathic pulmonary fibrosis (IPF). A total of 24 patients with IPF and 24 healthy controls were included in the study, four patients with IPF and four healthy controls were selected randomly to extract RNA. There were no other diseases such as hypertension and diabetes in the two groups. RNA from peripheral blood was extracted by high‑throughput sequencing and bioinformatics analysis was performed. Based on selected differentially expressed lncRNA and mRNA, gene ontology analysis was performed to screen out the tumor‑associated mRNA. A total of 20 samples were chosen to avoid variance due to individual differences. A total of 20 patients with IPF, and 20 controls were further studied, RNA extracted from peripheral blood was used to verify the lncRNA and mRNA levels. A total of 440 lncRNAs were identified to be upregulated and 1,376 downregulated according to the screening results of differential expression. High‑throughput sequencing and bioinformatics analysis demonstrated that the expression of CDKN2B‑AS1 decreased significantly in patients with IPF compared with healthy controls. The adjacent gene mRNA of CDKN2B‑AS1 was identified as CDKN2A, an important anti‑oncogene, which is concentrated on the p53 signaling‑pathway according to the Kyoto Encyclopedia of Genes and Genomes database. CDKN2A mRNA expression levels were lower in patients with IPF and higher in the control group. The expression of CDKN2B‑AS1 and CDKN2A mRNA was significantly lower in IPF group compared with in the control group (P<0.05). The results suggest the expression of the CDKN2B‑AS1 and adjacent gene, CDKN2A, are downregulated in the peripheral blood of patients with IPF, which activates the p53‑signaling pathway to promote lung cancer formation.

References

1 

Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, Nakamura Y, Inui N, Nakamura H and Chida K: Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 14:723–728. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Artinian V and Kvale PA: Cancer and interstitial lung disease. Curr Opin Pulm Med. 10:425–434. 2004. View Article : Google Scholar : PubMed/NCBI

3 

Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, et al: The transcriptional landscape of the mammalian genome. Science. 309:1559–1563. 2005. View Article : Google Scholar : PubMed/NCBI

4 

Mehler MF and Mattick JS: Noncoding RNAs and RNA editing in brain development, functional diversification, and neurological disease. Physiol Rev. 87:799–823. 2007. View Article : Google Scholar : PubMed/NCBI

5 

Kaelin WG Jr: The emerging p53 gene family. J Natl Cancer Inst. 91:594–598. 1999. View Article : Google Scholar : PubMed/NCBI

6 

American Thoracic Society. Idiopathic pulmonary fibrosis, . Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 161:646–664. 2000.PubMed/NCBI

7 

Silver N, Best S, Jiang J and Thein SL: Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. BMC Mol Biol. 7:332006. View Article : Google Scholar : PubMed/NCBI

8 

Busch SE, Moser RD, Gurley KE, Kelly-Spratt KS, Liggitt HD and Kemp CJ: ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma. Oncogene. 33:2665–2673. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Collard HR and Pantilat SZ: Dyspnea in interstitial lung disease. Curr Opin Support Palliat Care. 2:100–104. 2008. View Article : Google Scholar : PubMed/NCBI

10 

King TE Jr, Pardo A and Selman M: Idiopathic pulmonary fibrosis. Lancet. 378:1949–1961. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Spain DM: The association of terminal bronchiolar carcinoma with chronic interstitial inflammation and fibrosis of the lungs. Am Rev Tuberc. 76:559–566. 1957.PubMed/NCBI

12 

Song DH, Choi IH, Ha SY, Han KM, Lee JJ, Hong ME, Jeon K, Chung MP, Kim J and Han J: Usual interstitial pneumonia with lung cancer: Clinicopathological analysis of 43 cases. Korean J Pathol. 48:10–16. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Le Jeune I, Gribbin J, West J, Smith C, Cullinan P and Hubbard R: The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. 101:2534–2540. 2007. View Article : Google Scholar : PubMed/NCBI

14 

Matsushita H, Tanaka S, Saiki Y, Hara M, Nakata K, Tanimura S and Banba J: Lung cancer associated with usual interstitial pneumonia. Pathol Int. 45:925–932. 1995. View Article : Google Scholar : PubMed/NCBI

15 

Turner-Warwick M, Lebowitz M, Burrows B and Johnson A: Cryptogenic fibrosing alveolitis and lung cancer. Thorax. 35:496–499. 1980. View Article : Google Scholar : PubMed/NCBI

16 

Stack BH, Grant IW, Irvine WJ and Moffat MA: Idiopathic diffuse interstitial lung disease. A review of 42 cases. Am Rev Respir Dis. 92:939–948. 1965.PubMed/NCBI

17 

Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, Buccioli M, Piciucchi S, Sverzellati N, Dubini A, et al: The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 147:157–164. 2015. View Article : Google Scholar : PubMed/NCBI

18 

Aubry MC, Myers JL, Douglas WW, Tazelaar HD, Washington Stephens TL, Hartman TE, Deschamps C and Pankratz VS: Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc. 77:pp. 763–770. 2002; View Article : Google Scholar : PubMed/NCBI

19 

Nagai A, Chiyotani A, Nakadate T and Konno K: Lung cancer in patients with idiopathic pulmonary fibrosis. Tohoku J Exp Med. 167:231–237. 1992. View Article : Google Scholar : PubMed/NCBI

20 

Park J, Kim DS, Shim TS, Lim CM, Koh Y, Lee SD, Kim WS, Kim WD, Lee JS and Song KS: Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J. 17:1216–1219. 2001. View Article : Google Scholar : PubMed/NCBI

21 

Kishi K, Homma S, Kurosaki A, Motoi N and Yoshimura K: High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis. J Comput Assist Tomogr. 30:95–99. 2006. View Article : Google Scholar : PubMed/NCBI

22 

Kim Y, Kwon Y, Oh I, Kim K, Kim S, Ryu J, Yum H, Yong S, Lee K, Lee C, et al: National survey of lung cancer in Korea, 2005. J Lung Cancer. 6:67–73. 2007. View Article : Google Scholar

23 

Lee C, Kang KH, Koh Y, Chang J, Chung HS, Park SK, Yoo K and Song JS: Characteristics of lung cancer in Korea, 1997. Lung Cancer. 30:15–22. 2000. View Article : Google Scholar : PubMed/NCBI

24 

Hironaka M and Fukayama M: Pulmonary fibrosis and lung carcinoma: A comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. Pathol Int. 49:1060–1066. 1999. View Article : Google Scholar : PubMed/NCBI

25 

Takahashi T, Munakata M, Ohtsuka Y, Nisihara H, Nasuhara Y, Kamachi-Satoh A, Dosaka-Akita H, Homma Y and Kawakami Y: Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis. Cancer. 95:624–633. 2002. View Article : Google Scholar : PubMed/NCBI

26 

Kawasaki H, Ogura T, Yokose T, Nagai K, Nishiwaki Y and Esumi H: p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. Hum Pathol. 32:1043–1049. 2001. View Article : Google Scholar : PubMed/NCBI

27 

Oshikawa K and Sugiyama Y: Serum anti-p53 autoantibodies from patients with idiopathic pulmonary fibrosis associated with lung cancer. Respir Med. 94:1085–1091. 2000. View Article : Google Scholar : PubMed/NCBI

28 

Zhong G, Chen X, Fang X, Wang D, Xie M and Chen Q: Fra-1 is upregulated in lung cancer tissues and inhibits the apoptosis of lung cancer cells by the P53 signaling pathway. Oncol Rep. 35:447–453. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Liu ZH, Wang MH, Ren HJ, Qu W, Sun LM, Zhang QF, Qiu XS and Wang EH: Interleukin 7 signaling prevents apoptosis by regulating bcl-2 and bax via the p53 pathway in human non-small cell lung cancer cells. Int J Clin Exp Pathol. 7:870–881. 2014.PubMed/NCBI

30 

Li S, Li X, Zhao H, Gao M, Wang F and Li W: Overexpression of microRNA-125a-3p effectively inhibits the cell growth and invasion of lung cancer cells by regulating the mouse double minute 2 homolog/p53 signaling pathway. Mol Med Rep. 12:5482–5486. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Chuang CY, Liu HC, Wu LC, Chen CY, Chang JT and Hsu SL: Gallic acid induces apoptosis of lung fibroblasts via a reactive oxygen species-dependent ataxia telangiectasia mutated-p53 activation pathway. J Agric Food Chem. 58:2943–2951. 2010. View Article : Google Scholar : PubMed/NCBI

32 

Fu X, Ravindranath L, Tran N, Petrovics G and Srivastava S: Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol. 25:135–141. 2006. View Article : Google Scholar : PubMed/NCBI

33 

Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI

34 

Cao G, Zhang J, Wang M, Song X, Liu W, Mao C and Lv C: Differential expression of long non-coding RNAs in bleomycin-induced lung fibrosis. Int J Mol Med. 32:355–364. 2013. View Article : Google Scholar : PubMed/NCBI

35 

Ricciuti B, Mencaroni C, Paglialunga L, Paciullo F, Crinò L, Chiari R and Metro G: Long noncoding RNAs: New insights into non-small cell lung cancer biology, diagnosis and therapy. Med Oncol. 33:182016. View Article : Google Scholar : PubMed/NCBI

36 

Wang HM, Lu JH, Chen WY and Gu AQ: Upregulated lncRNA-UCA1 contributes to progression of lung cancer and is closely related to clinical diagnosis as a predictive biomarker in plasma. Int J Clin Exp Med. 8:11824–11830. 2015.PubMed/NCBI

37 

Khandelwal A, Bacolla A, Vasquez KM and Jain A: Long non-coding RNA: A new paradigm for lung cancer. Mol Carcinog. 54:1235–1251. 2015. View Article : Google Scholar : PubMed/NCBI

38 

Lopez-Pajares V: Long non-coding RNA regulation of gene expression during differentiation. Pflugers Arch. 468:971–981. 2016. View Article : Google Scholar : PubMed/NCBI

39 

Ebisuya M, Yamamoto T, Nakajima M and Nishida E: Ripples from neighbouring transcription. Nat Cell Biol. 10:1106–1113. 2008. View Article : Google Scholar : PubMed/NCBI

40 

Huang C, Yang Y and Liu L: Interaction of long noncoding RNAs and microRNAs in the pathogenesis of idiopathic pulmonary fibrosis. Physiol Genomics. 47:463–469. 2015. View Article : Google Scholar : PubMed/NCBI

41 

Mercer TR, Dinger ME, Sunkin SM, Mehler MF and Mattick JS: Specific expression of long noncoding RNAs in the mouse brain. Proc Natl Acad Sci USA. 105:pp. 716–721. 2008; View Article : Google Scholar : PubMed/NCBI

42 

Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E and Chang Y: Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 129:1311–1323. 2007. View Article : Google Scholar : PubMed/NCBI

43 

Willingham AT, Orth AP, Batalov S, Peters EC, Wen BG, Aza-Blanc P, Hogenesch JB and Schultz PG: A strategy for probing the function of noncoding RNAs finds a repressor of NFAT. Science. 309:1570–1573. 2005. View Article : Google Scholar : PubMed/NCBI

44 

Bayoglu B, Yuksel H, Cakmak HA, Dirican A and Cengiz M: Polymorphisms in the long non-coding RNA CDKN2B-AS1 may contribute to higher systolic blood pressure levels in hypertensive patients. Clin Biochem. 49:821–827. 2016. View Article : Google Scholar : PubMed/NCBI

45 

Timofeeva MN, Hung RJ, Rafnar T, Christiani DC, Field JK, Bickeböller H, Risch A, McKay JD, Wang Y, Dai J, et al: Influence of common genetic variation on lung cancer risk: Meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet. 21:4980–4995. 2012. View Article : Google Scholar : PubMed/NCBI

46 

Ørom UA, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G, Lai F, Zytnicki M, Notredame C, Huang Q, et al: Long noncoding RNAs with enhancer-like function in human cells. Cell. 143:46–58. 2010. View Article : Google Scholar : PubMed/NCBI

47 

Mattick JS: Linc-ing long noncoding RNAs and enhancer function. Dev Cell. 19:485–486. 2010. View Article : Google Scholar : PubMed/NCBI

48 

Cho RJ, Campbell MJ, Winzeler EA, Steinmetz L, Conway A, Wodicka L, Wolfsberg TG, Gabrielian AE, Landsman D, Lockhart DJ and Davis RW: A genome-wide transcriptional analysis of the mitotic cell cycle. Mol Cell. 2:65–73. 1998. View Article : Google Scholar : PubMed/NCBI

49 

Kruglyak S and Tang H: Regulation of adjacent yeast genes. Trends Genet. 16:109–111. 2000. View Article : Google Scholar : PubMed/NCBI

50 

Cohen BA, Mitra RD, Hughes JD and Church GM: A computational analysis of whole-genome expression data reveals chromosomal domains of gene expression. Nat Genet. 26:183–186. 2000. View Article : Google Scholar : PubMed/NCBI

51 

Quelle DE, Zindy F, Ashmun RA and Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:993–1000. 1995. View Article : Google Scholar : PubMed/NCBI

52 

Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE and Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:436–440. 1994. View Article : Google Scholar : PubMed/NCBI

53 

Huang SK, Scruggs AM, McEachin RC, White ES and Peters-Golden M: Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung. PLoS One. 9:e1070552014. View Article : Google Scholar : PubMed/NCBI

54 

Li J, Bi L, Sun Y, Lu Z, Lin Y, Bai O and Shao H: Text mining and network analysis of molecular interaction in non-small cell lung cancer by using natural language processing. Mol Biol Rep. 41:8071–8079. 2014. View Article : Google Scholar : PubMed/NCBI

55 

Cisneros J, Hagood J, Checa M, Ortiz-Quintero B, Negreros M, Herrera I, Ramos C, Pardo A and Selman M: Hypermethylation-mediated silencing of p14(ARF) in fibroblasts from idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 303:L295–L303. 2012. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Du, Y., Hao, X., & Liu, X. (2018). Low expression of long noncoding RNA CDKN2B-AS1 in patients with idiopathic pulmonary fibrosis predicts lung cancer by regulating the p53-signaling pathway. Oncology Letters, 15, 4912-4918. https://doi.org/10.3892/ol.2018.7910
MLA
Du, Y., Hao, X., Liu, X."Low expression of long noncoding RNA CDKN2B-AS1 in patients with idiopathic pulmonary fibrosis predicts lung cancer by regulating the p53-signaling pathway". Oncology Letters 15.4 (2018): 4912-4918.
Chicago
Du, Y., Hao, X., Liu, X."Low expression of long noncoding RNA CDKN2B-AS1 in patients with idiopathic pulmonary fibrosis predicts lung cancer by regulating the p53-signaling pathway". Oncology Letters 15, no. 4 (2018): 4912-4918. https://doi.org/10.3892/ol.2018.7910